Prosensa raises €23 million for RNA-based drugs

Wednesday 25 January 2012

Privately-owned Prosensa Therapeutics BV of the Netherlands has raised €23 million to support its pipeline which includes a Phase 3 RNA-modulating therapeutic for Duchenne muscular dystrophy. New Enterprise Associates Inc led the financing.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands